ISIS Pharmaceuticals, Inc.  

(Public, NASDAQ:ISIS)   Watch this stock  
Find more results for ISIS
51.92
+0.41 (0.80%)
Real-time:   10:57AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 51.31 - 52.22
52 week 22.25 - 62.66
Open 51.49
Vol / Avg. 140,743.00/2.47M
Mkt cap 6.13B
P/E     -
Div/yield     -
EPS -0.81
Shares 117.99M
Beta 1.45
Inst. own 90%
Dec 8, 2014
Isis Pharmaceuticals Inc to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting Conference Call - 9:00AM EST - Add to calendar
Dec 6, 2014
Isis Pharmaceuticals Inc at 56th ASH Annual Meeting and Exposition Add to calendar
Dec 2, 2014
Isis Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - 1:00PM EST - Add to calendar
Dec 1, 2014
Isis Pharmaceuticals Inc at Deutsche Bank BioFEST - 8:40AM EST - Add to calendar
Nov 20, 2014
Isis Pharmaceuticals Inc at Goldman Sachs US Emerging / SMID Cap Growth Conference
Nov 19, 2014
Isis Pharmaceuticals Inc at Stifel Healthcare Conference - Webcast
Nov 7, 2014
Q3 2014 Isis Pharmaceuticals Inc Earnings Call
Nov 7, 2014
Q3 2014 Isis Pharmaceuticals Inc Earnings Release
Nov 6, 2014
Isis Pharmaceuticals Inc at Nomura Biotechnology Conference
Oct 10, 2014
Isis Pharmaceuticals Inc to Discuss ISIS-SMN Rx Results Conference Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -60.54% -41.17%
Operating margin -48.78% -35.08%
EBITD margin - -28.44%
Return on average assets -13.28% -8.71%
Return on average equity -30.07% -21.61%
Employees 304 -
CDP Score - -

Address

2855 Gazelle Court
CARLSBAD, CA 92010
United States - Map
+1-760-9319200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Isis Pharmaceuticals, Inc. develops therapeutic drugs inhibiting cell protein synthesis. The Company's principal activity is to develop and market RNA(RiboNucleicAcid)-based novel drugs to treat important diseases such as cardiovascular diseases, diabetes and asthma

Officers and directors

Stanley T. Crooke M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Elizabeth L. Hougen Chief Financial Officer, Senior Vice President - Finance
Age: 52
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Chief Operating Officer, Corporate Secretary, Director
Age: 59
Bio & Compensation  - Reuters
Patrick R. O'Neil Esq. Senior Vice President - Legal, General Counsel
Age: 40
Bio & Compensation  - Reuters
C. Frank Bennett Ph.D. Senior Vice President - Antisense Research
Age: 57
Bio & Compensation  - Reuters
Richard S. Geary Ph.D. Senior Vice President - Development
Age: 56
Bio & Compensation  - Reuters
Brett P. Monia Ph.D. Senior Vice President - Drug Discovery and Corporate Development
Age: 52
Bio & Compensation  - Reuters
Joseph Loscalzo M.D., Ph.D. Director
Age: 62
Bio & Compensation  - Reuters
Spencer R. Berthelsen M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Breaux B. Castleman Independent Director
Age: 73
Bio & Compensation  - Reuters